TY - JOUR T1 - Presence of antiphospholipid antibodies in COVID-19: a case series study JF - Annals of the Rheumatic Diseases JO - Ann Rheum Dis SP - e73 LP - e73 DO - 10.1136/annrheumdis-2020-218100 VL - 80 IS - 5 AU - Luis M Amezcua-Guerra AU - Gustavo Rojas-Velasco AU - Malinalli Brianza-Padilla AU - Armando Vázquez-Rangel AU - Ricardo Márquez-Velasco AU - Francisco Baranda-Tovar AU - Rashidi Springall AU - Hector Gonzalez-Pacheco AU - Yaneli Juárez-Vicuña AU - Claudia Tavera-Alonso AU - Fausto Sanchez-Muñoz AU - Marisol Hernández-Salas Y1 - 2021/05/01 UR - http://ard.bmj.com/content/80/5/e73.abstract N2 - The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and its associated coagulopathy are particularly worrisome in patients with systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS), as these diseases carry an increased risk of thrombotic complications. Mathian et al recently reported the clinical course of COVID-19 in a series of 17 patients with SLE under chronic hydroxychloroquine therapy.1 Of note, only one patient (6%) presented thrombosis despite the fact that four patients (24%) had a history of secondary APS, and five patients (29%) were receiving oral anticoagulants. Antiphospholipid (aPL) antibodies were not measured in these patients during active SARS-CoV-2 infection.1 The American Society of Hematology recently stated that ‘at the current time, there are only very limited data on aPL antibodies in COVID-19 and it is unclear if they represent an epiphenomenon or are actually involved in any haemostatic abnormalities seen in COVID-19 disease’.2 Furthermore, almost all the available information refers to the lupus anticoagulant, with frequencies ranging from 45% to 87%.3 4 This paucity of data led us to test a panel of aPL antibodies in blood specimens from 21 patients hospitalised in the intensive care unit between 12 and … ER -